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Abstract
Rationale—Calmodulin (CaM) associates with cardiac ryanodine receptors (RyR2) as an
important regulator. Defective CaM-RyR2 interaction may occur in heart failure (HF), cardiac
hypertrophy, and catecholaminergic polymorphic ventricular tachycardia (CPVT). However, the
in situ binding properties for CaM-RyR2 are unknown.
Objective—We sought to measure the in situ binding affinity and kinetics for CaM-RyR2 in
normal and HF ventricular myocytes, estimate the percentage of Z-line localized CaM that is
RyR2-bound and test cellular function of defective CaM-RyR2 interaction.
Methods & Results—Using FRET (fluorescence resonance energy transfer) in permeabilized
myocytes, we specifically resolved RyR2-bound CaM from other potential binding targets, and
measured CaMRyR2 binding affinity in situ (Kd =10-20 nM). Using RyR2ADA/+ knock-in (KI)
mice, in which half of the CaM-RyR2 binding is suppressed, we estimated that >90% of Z-line
CaM is RyR2-bound. Functional tests indicated a higher propensity for Ca2+ waves production
and stress induced ventricular arrhythmia in RyR2ADA/+ mice. In a post myocardial infarction
(MI) rat HF model, we detected a decrease in the CaMRyR2 binding affinity (Kd ≈ 51nM, ~3 fold
increase) and unaltered FKBP12.6-RyR2 binding affinity (Kd ≈ 0.8nM).
Conclusions—CaM binds to RyR2 with high affinity in cardiac myocytes. Physiologically,
CaM is bound to >70% of RyR2 monomers and inhibits SR Ca2+ release. RyR2 is the major
binding site for CaM along the Z-line in cardiomyocytes and dissociating CaM from RyR2 can
cause severe ventricular arrhythmia. In HF, RyR2 shows decreased CaM affinity, but unaltered
FKBP12.6 affinity.
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INTRODUCTION
Approximately 50% of heart failure (HF) patients die of ventricular arrhythmia and sudden
cardiac death 1. It is known that ryanodine receptor type 2 (RyR2) mediated Ca2+ leak from
the sarcoplasmic reticulum (SR) during diastole can activate inward current via Na/Ca
exchange (NCX) 2 and evoke delayed afterdepolarizations (DADs). In HF, there is enhanced
diastolic SR Ca2+ leak via RyR2 and other electrophysiological changes that greatly enhance
the propensity for DADs and triggered cardiac arrhythmias, a leading cause of ventricular
tachyarrhythmia and sudden cardiac death.3-6 Thus, RyR2 has emerged as a potential
therapeutic target for treating HF and arrhythmia. Stabilizing RyR2 and preventing
abnormal Ca2+ leak (without affecting normal excitation-contraction coupling) may be a
valid therapeutic approach.
Calmodulin (CaM) is an important RyR2 regulator, but has multiple cellular targets. CaM
has two pairs of globular Ca2+ binding E-F hand domains connected by a flexible linker.7 At
high [Ca2+], Ca2+ binds cooperatively to CaM inducing a conformational change that
translates intracellular [Ca2+] signals to diverse processes via many targets, including:
myosin light chain kinase, calcineurin, nitric-oxide synthase, phosphodiesterase, adenylyl
cyclase, Ca2+/CaM-dependent kinase (CaMK), Ca2+-activated potassium channels, L-type
Ca2+ channels (LTCCs), and RyRs.8-11
CaM binds to RyR2 stoichiometrically (four CaMs per tetrameric RyR2) and amino acids
3583-3603 on RyR2 are essential for this interaction.12-14 CaM inhibits RyR2 opening at all
[Ca2+] and as such may be a critical regulator of SR Ca2+ release.13,14 Cryo-EM based
three-dimensional reconstruction studies showed that Ca2+-free CaM (apoCaM) binds in the
RyR cytosolic domain 3, within 60-70Å from FKBP12.6 bound on the same RyR face,15,16
and we have demonstrated that fluorescence resonance energy transfer (FRET) can be
measured between these partners bound to either RyR1 or RyR2.17,18 FKBP12.6 was
reported to bind RyR2 tightly as an important regulator in RyR2 gating but aspects of the
FKBP12.6-RyR2 interaction and function remain controversial.19-22 It was also reported that
CaM could stabilize the RyR2 in the closed state during diastole and facilitate the
termination of Ca2+ release by decreasing the probability of channel reopening and
prolonging the closed time.23 Defective CaM-RyR2 interaction has potentially broad
implication in cardiac pathology. Mutations of critical residues in the highly conserved CaM
binding region can severely decrease, or abolish CaM binding to RyR2 and cause severe
hypertrophic cardiomyopathy and early death in animals.13,24 In non-ischemic HF animal
models, CaM binding to RyR2 was decreased.25,26 A recent study indicates that defective
CaM binding to RyR2 is also involved in catecholaminergic polymorphic ventricular
tachycardia (CPVT)-associated RyR2 dysfunction.27 So, the CaM-RyR2 interaction may be
critical for arrhythmias and HF pathogenesis.
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Here, we used FRET to resolve RyR-bound CaM from other CaM targets, and in the native
myocyte environment, to characterize CaM-RyR2 interaction properties for normal and HF
cardiomyocytes. Knock-in (KI) heterozygous mice (RyR2ADA/+),13 with genetically
disrupted CaM-RyR2 association (W3587A/L3591D/F3603A) were used to estimate what
percentage of Z-line bound CaM is RyR2-bound, and test for increased arrhythmia
susceptibility in both myocytes and intact animals under acute stress. This would be
analogous to what is seen in CPVT, which is linked to RyR2 mutations.28,29 This ADA
mutant RyR2 is not expected to change CaM effects at other CaM targets. Human mutations
in CaM have recently also been associated with CPVT, which may be partially recapitulated
by these RyR2ADA/+ mice.30
METHODS
Ventricular myocytes were isolated as previous described,22 from hearts of WT or
RyR2ADA/+ KI mice and Sprague-Dawley rats (control and 12 weeks after HF induced by
coronary ligation31,32). FKBP12.6 and CaM were labeled with Alexa Fluor 488 and 568
(AF488 and AF568) as described, which bind to and regulate RyRs in SR like wild type
proteins.17,18 Some myocytes were saponin-permeabilized and bathed in physiological
internal solutions. Fluorescent FKBP12.6 and CaM (F-FKBP and F-CaM) and 25 μM Fluo-4
(to measure [Ca]i) were used with confocal imaging.22,33 ECGs were recorded in
RyR2ADA/+ and WT mice during isoproterenol (ISO, 2mg/kg) and caffeine (120mg/kg)
challenges. Further details are in the Online Methods.
RESULTS
Steady-state binding of CaM to RyR2
Pre-depletion of endogenous CaM by suramin—RyR2s are concentrated at Z-lines,
which is also true for CaM,34 and ~90% of apoCaM binding sites are occupied by
endogenous CaM.34 Online Fig. IAi shows the F-CaM Z-line striation pattern after 60 nM F-
CaM was washed in. Suramin (5 μM) wash-in abolished striations within 60 s (Online Fig.
IAii), indicating F-CaM dissociation from Z-line sites. After suramin-dependent stripping
and subsequent wash-out (20 min), F-CaM rebound at Z-lines, restoring striations (Online
Fig. IAiii). Before suramin treatment, F-CaM binding kinetics were slow, time constant τ =
11.5 min (Online Fig. IB) which represents F-CaM replacing endogenous RyR-bound
CaM.34 After depleting endogenous RyR-bound CaM with suramin, F-CaM binding was
much faster (τ = 2 min; Online Fig. IC), reflecting F-CaM binding to unoccupied binding
sites. Bmax was not significantly altered by suramin pretreatment, indicating that suramin
completely depleted endogenous Z-line bound CaM, and that CaM and suramin binding are
completely reversible.
Steady-state CaM-RyR2 binding affinity—Strong FRET between F-FKBP and F-CaM
is effective in distinguishing CaM bound to RyR2 vs. other CaM targets.18 After suramin
pretreatment, 100 nM F-FKBP (donor) was washed-in to saturate FKBP binding sites on
RyR2.18,22 Then different F-CaM (acceptor) concentrations were washed-in and allowed to
reach steady state (20-120 min). RyR2-bound CaM is detected through FRET by sensitized
emission (SE). Fig. 1A shows fluorescent striations with F-FKBP excitation at 488 nm and
Yang et al. Page 3






















two different [F-CaM] in both donor (green) and acceptor (red) channels. In FRET-based Kd
measurements, as [F-CaM] increases, donor fluorescence decreases (donor quench), while
acceptor fluorescence increases (enhanced acceptor fluorescence, EAF). The fluorescence
intensity in the acceptor channel (difference between Z-and M-line fluorescence) is due to
EAF (FRET) and reflects the amount of CaM specifically bound to RyR2. The binding
isotherm in Fig. 1B, is well described by a specific binding curve with a single binding site
(Kd = 18 ± 2 nM). We also calculated Kd from donor quenching (21 ± 3 nM; Online Fig. II)
in agreement with that.
To test whether FRET occurs between one donor and one acceptor, in Fig. 1C we plotted
donor signal (y-axis) vs. acceptor signal (x-axis) for the same [F-CaM], from experiments
shown in Fig 1B. The dependence of donor fluorescence (F-FKBP; decreasing due to FRET)
on the acceptor fluorescence (FCaM; increasing FRET) is linear, consistent with
bimolecular FRET.35 This suggests that FRET is exclusively between FKBP12.6 and CaM
bound to the same face of the RyR2 (not to another nearby site).18
Total CaM at Z-line—Using direct F-CaM excitation (543 nm) rather than FRET, we also
measured the apparent Kd for total CaM bound at the Z-line (i.e., CaM bound to RyR2 plus
other sites along the Z-line). Fig. 1D shows the Z-line striations at two different [F-CaM].
The plot of peak height reveals a single saturable binding component for F-CaM at the Z-
line with Kd = 17 ± 2 nM (Fig. 1E). Kd values for RyR2-bound CaM (Fig.1B) and for total
CaM bound at the Z-line (Fig. 1E) are very similar. One possible explanation is that RyR2 is
the quantitatively dominant CaM binding site in the Z-line. The other is that several CaM
binding sites have similar affinities. Through linear bath [F-CaM] calibration (Fig. 1F), we
can infer the concentration of Z-line bound F-CaM in permeabilized myocytes. The
maximum bound CaM at the Z-lines (Bmax, Fig. 1E) is 1.2 μM, similar to our prior work,36
and consistent with the Bmax for FKBP12.6 in rat myocytes.22
Kinetics of CaM binding to RyR2
FRET-based measurement of kon and koff during wash-in/out in myocytes—
After CaM depletion, permeabilized myocytes were saturated with F-FKBP (100 nM).
Using FRET, we characterized CaM-RyR2 association (kon) and dissociation (koff) rate
constants in F-CaM wash-in/out experiments (Fig. 2A). During wash-out, fluorescent
striations gradually dissipated along a single-exponential decay (τ = 4.5 min), which
corresponds to koff = 0.22 ± 0.01 min-1 (n=5). For wash-in, CaM-RyR2 association rate is a
function of kon, koff and [F-CaM] (kwash-in = kon [CaM] + koff). Using the koff above and the
wash-in data, we calculated kon =18.9 ± 1.6 x 106 min-1M-1 (n=5). These kon and koff values
correspond to Kd = 12 ± 1 nM (koff/kon), which agrees with the steady-state binding results
above.
FRAP-based measurement of kon and koff in myocytes—Permeabilized myocytes
were first equilibrated with saturating F-FKBP (100nM) and with [FCaM] in the Kd range.
After photobleaching the acceptor by 543 nm excitation in the central region of the cell (Fig.
2B), we monitored striation recovery (FRAP). FRAP reflects recovery of CaM-RyR2
binding, in which the photobleached RyR-bound F-CaM dissociates and is replaced by fresh
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F-CaM from the bath. In Fig. 2C, kFRAP was fit to a single-exponential function for two
different bath [F-CaM], upon which FRAP is dependent (kFRAP= kon[F-CaM] + koff). The
values of kon and koff are obtained from linear regressions (Fig. 2D). Both kon = 14.5 ± 2.5
x106 min-1 M-1 and koff = 0.144 ± 0.05 min-1 agree well with the wash-in/out experiments
(Fig. 2A), and give a similar Kd (10 ± 2 nM).
Percentage of total Z-line CaM that is RyR2-bound—KI mice with genetically
disrupted CaM-RyR2 interaction are used here (along with WT mice) to estimate the
percentage of total Z-line-bound CaM that is RyR2-bound. These KI mice express RyR2
with a triple-mutation (RyR2-W3587A/L3591D/F3603A, RyR2ADA/+) that prevents high-
affinity binding of CaM.13 Homozygous (RyR2ADA/ADA) mice all die within 16 days of
birth with a severe HF phenotype, loss of T-tubule/junctional couplings and ~70% decrease
in RyR2 expression, making them unsuitable here.13,24 However, the heterozygous mice
(RyR2ADA/+) have no evidence of HF or structural defects, and exhibit normal life-span and
RyR2 expression levels.13 We find that RyRADA/+ myocytes exhibit reduced F-CaM
binding both to the RyR2 (by FRET), and at the Z-line (by direct F-CaM excitation; Fig.
3A,B). For RyR2ADA/+, there is a 50% ± 2% reduction in FRET at saturating [F-CaM]
(FRETmax), with no significant change in Kd (Fig. 3C). That fits the expectation that in
RyR2ADA/+ mice ~50% of the RyR2 monomers have the triple-mutation and defective CaM
binding. There is also a 46% ± 2% reduction of total CaM at the Z-line (Fig. 3D), which is
therefore primarily due to the 50% decrease in CaM binding to RyR2. This suggests that
~92% of Z-line localized CaM is bound to RyR2. We also measured RyR2 monomer
expression as total binding (Bmax) of FKBP12.6 (Online Fig. III).22 FKBP12.6 binding was
identical in RyR2ADA/+ vs. WT myocytes, confirming an unaltered total number of RyR2
monomers, in line with unaltered Bmax of [3H]-ryanodine binding in these mice.13
Ca2+ sparks in permeabilized RyR2ADA/+ KI mouse myocytes—Saponin-
permeabilized myocytes are powerful tools for the evaluation of diastolic SR Ca2+ leak. The
free [Ca]i can be tightly controlled and it avoids complications due to LTCCs, which can
trigger RyR2-mediated Ca2+ release. However, a potential disadvantage of this method is
that some cellular contents (like endogenous proteins) can be lost due to wash-off. Since the
endogenous CaM associated with RyR2 may be washed off within 10 min (Fig 2A), we
modified the permeabilization protocol, for Ca2+ spark measurements, to limit this
disadvantage. For Ca2+ spark measurements, myocytes were exposed to saponin (50 μg/ml)
for only 20-30 s instead of the 3 min used above for CaM wash-in. Online Fig. IV shows
that after 20-30 s permeabilization, Ca2+ sparks were readily detected in myocytes after 20
min exposure to F-FKBP, F-CaM and fluo-4. However, there was no visible striated pattern
observable for F-FKBP, F-CaM, or FRET. This indicates that fluo-4 can enter the cell with
this gentler permeabilization, but proteins (e.g. CaM and FKBP12.6) cannot. With the 3 min
permeabilization protocol, both FRET striation pattern and Ca2+ sparks were detected,
indicating that all 3 probes entered the cell. This shows that 20-30 s permeabilization can
also effectively limit FKBP12.6 and CaM wash-out during the time of Ca2+ spark
measurement. Thus, we can make the Ca2+ spark measurement in the relatively native
cellular environment with respect to CaM and FKBP12.6 concentrations.
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Using this approach, we measured diastolic SR Ca2+ leak as Ca2+ sparks within 15-20 min
of permeabilization. Fig. 4A, B shows that, at 50 nM [Ca2+], spark frequency was
significantly higher in RyR2ADA/+ versus WT mice (8.9 ± 0.3 vs. 6.4 ± 0.5 s-1 per 100 μm),
which tended to lower SR Ca2+ content in RyR2ADA/+ versus WT (albeit insignificantly;
Fig. 4B). Ca2+ spark frequency depends steeply on SR Ca2+ content,37 such that the new
steady state spark frequency underestimates the magnitude of the primary effect. The
increased Ca2+ spark frequency could not be prevented by the specific CaMKII inhibitor
AIP (Fig. 4B), ruling out a contribution of CaMKII. These results are consistent with half of
the RyR2 monomers lacking CaM, allowing higher RyR2 activity.
In a second series of spark experiments we compared the effect of endogenous CaM (as
above) with CaM washout and re-admission in WT and RyR2ADA/+ mice (Online Fig. V).
For WT CaM, wash-off increased Ca2 spark frequency, Ca2+ spark full duration at half-
maximum (FDHM), and full width at half-maximum (FDHM). These effects were reversed
with CaM re-addition. However, in RyR2ADA/+ myocytes the baseline Ca2+ spark
frequency, FDHM and FWHM were already high (comparable to that in CaM-free WT
myocytes), and were not influenced by CaM washout or re-admission. Thus, even 500 nM
CaM cannot reverse the high Ca2 spark frequency caused by defective CaM-RyR2
interaction (Online Fig. V).
We also increased intracellular [Ca2+] to 100 nM, close to the threshold for Ca2+ waves in
WT mouse myocytes, to further test the propensity for DADs or arrhythmogenesis. The
increased [Ca2+] mimics a Ca2+ loading stress in permeabilized cells, since both cytosolic
and SR Ca2+ load are increased. In RyR2ADA/+ mice ~90% of myocytes produced Ca2+
waves vs. only ~10% of myocytes for WT mice (Fig. 4C-D), again without a significant
difference in Ca2+ SR load (Fig. 4D). The caffeine-induced Ca transients were induced
during sweeps where no waves occurred, to limit underestimation of SR Ca2+ content that
would occur in the wake of a wave. All these data indicate that the ADA CaM-binding
mutation in RyR2, increases diastolic SR Ca2+ leak under resting conditions, and increases
propensity for arrhythmogenic Ca2+ wave production under moderate Ca2+ loading
conditions.
Ca2+ transients in RyR2ADA/+ KI mouse in intact myocytes—We also measured
Ca2+ transients in intact ventricular myocytes (Fig. 5A) with or without isoproterenol (ISO,
50 nM) present, and SR Ca2+ content was evaluated through rapid caffeine application. In 1
Hz field stimulation at baseline, RyR2ADA/+ myocytes behave similar to WT in Ca2+
transient amplitude, time constant of Ca2+ transient decline, SR Ca2+ content, and fractional
SR Ca2+ release (Fig. 5B-E). While exposure to ISO (50 nM) had similar effects on Ca2+
transient amplitude in both WT and RyR2ADA/+, the time constant of [Ca2+]i decline was
longer, SR Ca2+ content was lower and fractional SR Ca2+ release was increased in
RyR2ADA/+ vs. WT (Fig 5C-E). The more sensitive RyR2ADA/+ and higher Ca2+ loading in
50 nM ISO may cause the prolonged twitch [Ca2+]i decline (delayed shut-off of release, as
demonstrated under analogous conditions in CaMKIIδC overexpressing mice that lack
phospholamban38). The exacerbated leak in RyR2ADA/+ mice may also limit the rise in SR
Ca2+ content induced by ISO, like the reduced maximal achievable SR Ca2+ content in HF
or ISO treated myocytes.24,39 Figure 6 also shows that in RyR2ADA/+ myocytes, ISO
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increased the propensity for Ca2+ waves that trigger action potentials. That is, the transition
from Ca2+ wave to spatially synchronized global Ca2+ release was necessarily synchronized
by a triggered action potential. These triggered events could reflect increased
arrhythmogenic risk in RyR2ADA/+ mice, analogous to CPVT.
Ventricular arrhythmia in RyR2ADA/+ KI mouse—To test whether the RyR2ADA/+ KI
mice are more susceptible to CPVT-like arrhythmias, we measured ECGs in intact mice
during injection of ISO plus caffeine as has been done in CPVT mouse models.40 Figure 7A
shows that RyR2ADA/+ KI mice developed severe stress inducible ventricular arrhythmia.
All RyR2ADA/+ mice exhibited sustained bigeminy (>20min), a precursor for ventricular
tachycardia (VT, Fig 7B). In 60% of RyR2ADA/+ mice, bidirectional VT was induced (Fig
7B), and episodes of VT were frequent (4.5/mouse) in RyR2ADA/+ mice. In contrast, none of
the WT mice exhibited inducible arrhythmia in this protocol.
Binding affinity of CaM/FKBP12.6 to RyR2 in HF myocytes—We measured CaM-
RyR2 affinity in a rat HF model induced by coronary ligation. Twelve weeks post-infarct
these rats exhibit increased heart/body weight ratio, increased LV diastolic dimensions
(LVDD) and decreased fractional shortening.31,32 Other HF molecular markers (ANP, BNP,
TNF-α) are also increased in this model.32 The HF rats used here had reduced fractional
shortening (<20% vs. normal: 46%) and elevated LVDD (see Online Fig. VI). We used
FRET to measure the CaM-RyR2 affinity. In HF vs. normal myocytes, the CaM-RyR2
affinity was ~3-fold lower (Kd=51±4 nM; Fig. 8A). We also performed paired experiments
with sham rats, with [F-CaM] near the Kd and saturating (FRETmax) (Fig 8B). At [F-CaM]
near WT Kd, changes in affinity are readily detected, and binding was significantly lower in
HF. FRETmax was unaltered.
FKBP12.6 was suggested to also be a critical RyR2 stabilizer, with decreased affinity in HF
(although this is controversial).41 Using methods previously described,22 we measured, for
the first time within HF myocytes, the FKBP12.6-RyR2 affinity (Kd = 0.8 ± 0.1 nM; Fig.
8C). This is almost identical to the Kd we previously measured in normal rat myocytes under
the same conditions (0.7 ± 0.1 nM).21 We also performed paired experiments (as for CaM).
We found no significant changes in FKBP12.6-RyR2 binding either at subsaturating or
saturating [F-FKBP] in sham vs. HF rat myocytes (Fig. 8D).
DISCUSSION
Here we resolved CaM binding to RyR2 vs. other Z-line binding partners, and characterized
CaM-RyR2 binding properties (Kd and on/off rates) in permeabilized ventricular myocytes
by 3 independent methods (Online table I). RyR2ADA/+ KI mice with disrupted CaM-RyR2
binding, were used to determine that >90% of Z-line CaM is bound to RyR2. Functional
consequences of reduced CaM binding to RyR2 were detected using Ca2+ measurements in
WT vs. RyR2ADA/+ KI myocytes, with CaM wash-out from WT myocytes, and
arrhythmogenesis tests in mice. We also found CaM-RyR binding affinity to be reduced in
HF myocytes. These results provide important new insights into understanding CaM-RyR2
interactions in normal and HF myocytes.
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CaM-RyR2 binding properties in myocytes
CaM, as a key regulator of RyR2 function, may be important in myocyte Ca2+ homeostasis
in HF, cardiac hypertrophy, and CPVT. But in situ CaM-RyR2 binding properties were
previously unknown. Using three independent methods, we demonstrated that CaM binds to
RyR2 with high affinity (Kd=10-20 nM) in myocytes at 50 nM [Ca2+]i. Considering the
measured free [CaM] in myocytes (50-75 nM),34 the majority of RyR2 monomers
(~70-90%) have CaM bound, such that CaM can influence local [Ca2+]i by inhibiting RyR2
opening at physiological [Ca2+].12-14,23,26,42 The CaM-RyR2 binding affinity we measured
in myocytes is higher than in cell lysates and SR vesicles.17,27 This could be due to
differences in experimental conditions or subcellular fractionation effects. In SR vesicles,
essential partners from the cellular environment may be lost, or post-translational
modifications of RyR2 might occur (e.g., phosphorylation or oxidation), which can alter
CaM-RyR2 affinity.23,43 Using three methods, we measured very similar CaM-RyR2
affinities that are consistent with CaM's physiological function.13,23 This supports that our
Kd measurements (10-20 nM) are valid for the CaM-RyR2 binding affinity in the native
cardiac myocyte environment.
According to our data, CaM-RyR2 has a relatively slow koff (~0.2 min-1), meaning that the
average dwell-time for CaM on RyR2 is ~5 min, under resting conditions. In addition, high
[Ca2+]i (500 nM) strengthens CaM binding to RyR/Z-lines and greatly slows CaM
dissociation.18,34 Hence, increased CaM-RyR2 affinity during the Ca2+ transient (<1 s)
would further enhance CaM saturation at all RyR2 monomers in the physiological beat-to-
beat situation. Furthermore, it was proposed that CaM can switch between two binding sites
separated by ~33Å on RyR1 during each cardiac cycle.44,45 The two-site switch involves
two sets of association and dissociation process, which seems unlikely to occur within the
very short systolic time, according to our measured kinetics. Taken together, these suggest
that CaM is a resident RyR2-associated protein anchored at least to residues 3583-3603.
This interpretation is consistent with a recent cryo-EM report placing apo- and Ca-CaM at
the same location within the RyR2 map.46 However, we cannot exclude the possibility of
beat-to-beat RyR2 regulation by CaM because homozygous RyR2ADA/ADA myocytes
exhibit prolonged Ca2+ transient and spark durations. That is consistent with the possible
importance of resident CaM for RyR2 shut-off.13,24,47 During a Ca2+ transient, RyR2
opening and conformation change could alter anchored CaM function, where binding of
Ca2+ to CaM would facilitate the termination of Ca2+ release.
Nearly all Z-line bound CaM is on RyR2
An important finding here is that >90% of the total Z-line associated CaM is bound to
RyR2, i.e., ~1.2 μM (Fig. 1E). This is consistent with our FKBP12.6 Bmax measurements,22
and with the estimated concentration of RyR2 monomers in rat ventricular myocytes,48
implying that there may be ~70 nM of non-RyR2 CaM-binding sites at the Z-line. Since the
LTCC also binds CaM at the Z-line, and there are ~32 RyR2 monomers per LTCC in rat
myocytes,48 LTCC would bind about 40 nM CaM, consistent with our findings. It is clear
that RyR2 is the quantitatively dominant CaM binding site at the Z-line. Total cellular
[CaM] in rat cardiac myocytes is 2-6 μM, and varies somewhat with species.49 We infer that
a reduction in CaM-RyR2 binding affinity, as in HF or CPVT,25-27 might also shift CaM's
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distribution among different binding targets. Since free [CaM] is only 50-100 nM in
myocytes (>95% is bound) even at diastolic [Ca2+]i there is likely to be competition among
target sites for available CaM.34
Defective CaM-RyR2 interaction and SR Ca2+ release, CPVT
Here RyR2ADA/+ mice13 were used to assess CaM binding at the RyR2 and Z-line
quantitatively, but this also alters SR Ca2+ leak which provides a functional correlate.
Homozygous RyR2ADA/ADA mice have altered SR Ca2+ release, but also exhibit profound
HF, death within ~2 weeks of birth, 70% reduction in RyR2 expression T-tubule
disorganization.13,24 Remarkably RyR2ADA/+ mice have normal lifespan, structure and
RyR2 expression with no hypertrophy.13 This is similar to KI mice carrying a CPVT1
mutation (RyR2-R2474S),28,50 where heterozygous mice survive without hypertrophy
similar to WT, but the homozygous KI is lethal. Decreased CaM-RyR2 binding affinity has
also been reported in CPVT1 KI mice under stress conditions known to be
arrhythmogenic.27 Thus, the RyR2ADA/+ mice studied here resemble a CPVT1 model, and
we also assessed abnormal SR Ca2+ release and stress-induced arrhythmic events in these
mice.
Baseline Ca2+ transients were similar between RyR2ADA/+ and WT mice, consistent with
prior hemodynamic data, indicating functional normalcy of these mice (vs. WT
littermates).13 RyR2ADA/+ myocytes exhibited a moderate increase in Ca2+ spark frequency
at baseline. The moderate Ca2+ leakiness may explain why the heterozygous mice survive as
long as WT controls (unlike homozygous RyR2ADA/ADA). Recently, Yamaguchi et al.51
showed that the single RyR2-L3591D mutant (which also reduces RyR2-CaM binding),
when homozygous in KI mice, increases RyR2 open probability at diastolic [Ca2+], but is
much better tolerated vs. the RyR2ADA/ADA triple mutation. These results are consistent
with the CPVT phenotype, where under resting condition the CPVT patients are completely
normal.
Catecholamine challenge (ISO) in RyR2ADA/+ further exacerbated SR Ca2+ leak, limited the
ISO-induced lusitropy and SR Ca2+ loading, but the Ca transients were still similarly
enhanced (vs. WT; Fig 5). We infer that this is because there is fractional SR Ca2+ release in
the RyR2ADA/+ mice with ISO. So this mouse seems adapted to have normal adrenergic
inotropic response, but the SR is pushed closer to instability. In particular, we suspect that
the limited lusitropic effect and reduced SR Ca2+ content after ISO in RyR2ADA/+ mice may
be due to the dramatically increased SR Ca2+ leak, especially because Yamaguchi et al.13
found SR Ca-ATPase-dependent uptake rate in RyR2ADA/+ mice was normal. That agrees
with single-channel RyR2 recordings suggesting that defective CaM-RyR2 interaction
delays RyR2 closure.23
Despite the relative normalcy of Ca2+ transients in RyR2ADA/+ myocytes, the exacerbation
of leak may limit maximal SR Ca2+ content, just as seen for both ISO treatment alone and
HF alone.25,39 This might limit cardiac reserve. More importantly, this enhanced leak in
RyR2ADA/+ increases Ca2+ waves and triggered activity in myocytes and whole animal
arrhythmias in response to catecholamine challenge (Fig 4, 6 and 7). This again recapitulates
the situation in CPVT1 KI mice and patients.28,29 In particular, the bidirectional VT seen in
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RyR2ADA/+ (but not WT mice) is clinically diagnostic for CPVT.29 Although this RyR2
ADA mutation is not a known disease-linked mutation in humans, it causes a CPVT-like
phenotype. There are also two recent CaM mutations that are associated with CPVT in
patients,30 and the CPVT phenotype may well result from effects of these mutant CaMs
analogous to our RyR2ADA/+ mouse results here.
We cannot exclude the possibility that the ADA triple mutation alters RyR2 domain
interactions, which might also contribute to the functional effects observed. However, the
similarity between the RyR2ADA/+ and simply depleting CaM from the WT RyR2 (Online
Fig V) convinces us that the loss of CaM binding is the major factor in RyR2ADA/+ mice
causing abnormal SR Ca2+ leak and arrhythmias. We recently also showed that CaM
binding can stabilize RyR2 conformation in a more stably closed (zipped) state where access
of an unzipping peptide is supressed.52
CaM-RyR2 binding affinity in HF myocytes
Prior work in HF rabbit and canine models demonstrated reduced RyR2-bound CaM, based
on co-immunoprecipitation and biochemical analysis,25,26 but total CaM expression was
unaltered.25 Here we directly measured CaM and FKBP12.6 affinity for RyR2 in situ in HF
myocytes. We found a three-fold lower CaM affinity in HF myocytes, while FKBP12.6
affinity was unaltered. This quantitative information allows novel inferences. Assuming that
free [CaM] in HF myocytes is 50-100 nM,34 the saturation of RyR2 monomers with CaM
would be expected to drop from 70-90% to 50-70% in HF. This lower RyR2 saturation with
CaM may have an analogous functional effect to those that we found in the RyR2ADA/+
mice, where only 50% of RyR2 can bind CaM. The implication is that reduced CaM binding
to RyR2 may contribute to the known increased SR Ca2+ leak in HF,4,25 and to the
incidence of arrhythmias, which are responsible for 50% of HF deaths.1 Furthermore,
attenuated CaM-RyR2 association in HF could allow other intracellular CaM targets of
lower affinity to be better activated, since RyR2 is a major CaM site in myocytes.11 One
such site is CaMKII which is activated in HF and contributes to SR Ca2+ leak and
arrhythmogenesis by phosphorylation and activation of RyR2.25 Thus, decreased CaM-
RyR2 association in HF may synergize with other regulatory pathways to exacerbate cardiac
dysfunction and arrhythmias.
Overall, the HF-associated SR Ca2+ leak is a complicated process involving several factors
(e.g., CaM, CaMKII, FKBP12.6, redox modification, etc.). Here, for the first time, we
measured directly the in situ binding affinity of RyR2 for FKBP12.6 in HF myocytes, but
found it to be unaltered vs. control. We conclude that CaM binding to RyR2 may be an
important physiological regulator of RyR2 gating in cardiac myocytes, and that defects in
this binding in HF or CPVT might constitute an important molecular mechanism of
triggered arrhythmias suitable for therapeutic targeting.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Yang et al. Page 10
























Supported by NIH grants R01-HL092097 (DMB, RLC), P01-HL080101 (DMB), and R01-HL073051 (GM), and by
Banyu Life Science Foundation International (TO).
Nonstandard Abbreviations and Acronyms
τ time constant
AC adenylyl cyclase
ADA W3587A/L3591D/F3603A triple mutation of RyR2






CPVT catecholaminergic polymorphic ventricular tachycardia
VT ventricular tachycardia
DAD delayed afterdepolarization
EAF enhanced acceptor fluorescence
F fluorescent
FDHM full duration at half maximum
FKBP12.6 FK506 binding protein
FRAP fluorescence recovery after photobleaching
FRET fluorescence resonance energy transfer
FRETmax FRET value at saturating acceptor concentration.





koff dissociation rate constant
kon association rate constant
LTCC L-type calcium channels
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LVDD left ventricular diastolic dimension
LVSD left ventricular systolic dimension
MI myocardial infarction
NCX Na/Ca exchanger
NOS nitric oxide synthase
NT normal Tyrode's solution
PDE phosphodiesterase
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• Calmodulin (CaM) binds to multiple cellular targets, including the SR Ca2+
release channel (RyR2) in cardiomyocytes. CaM binding reduces RyR channel
opening and can reduce SR Ca2+ leakiness.
• Abnormal SR Ca2+ leak is thought to contribute to dysfunction and arrhythmias
in CPVT (Catecholaminergic polymorphic ventricular tachycardia) and heart
failure (HF).
• FK506-binding protein 12.6 (FKBP12.6) binds to RyR2 with high affinity and
may also stabilize RyR gating, but results are controversial.
What New Information Does This Article Contribute?
• In the native cardiac myocyte environment with 50 nM [Ca2+]i, CaM binds to
RyR2 (and at the Z-line) with high affinity (Kd = ~ 15 nM).
• More than 90% of the CaM at the Z-line is RyR2 bound in cardiac myocytes.
• CaM dissociation from RyR2 or lack of binding to mutant RyR2 can lead to
abnormal SR Ca release in the form of increased Ca sparks, Ca waves, triggered
activity and arrhythmias at the whole animal level.
• These arrhythmogenic features recapitulate RyR2 changes seen in CPVT and
HF.
• In a post-myocardial infarction rat HF model, RyR2-CaM binding affinity is
reduced ~3 fold, while FKBP12.6 affinity is unaltered.
CaM is known as a mediator of Ca2+ signals, and it can bind to and alter RyR properties.
However, little quantitative data are available about CaM-RyR interaction and function in
native cardiac myocytes. We used confocal fluorescence microscopy to measure the in
situ binding kinetics and affinity of CaM for RyR in normal myocytes and in myocytes
from mice expressing a mutant RyR that cannot bind CaM (CPVT-like model) and from
rats with post-MI-induced HF. Using fluorescence resonance energy transfer (FRET), we
can distinguish RyR2-bound CaM from CaM bound to other sites in the myocyte. More
than 90% of the CaM that is already highly concentrated along the Z-lines of the myocyte
is bound directly to RyR. We also found that CaM binding to RyR was reduced in the
CPVT-like and HF models and it that causes enhanced SR Ca2+ leak leading to
arrhythmogenic events (. Reduced CaM binding to RyR in cardiac myocytes resulting in
enhanced SR Ca leak may be an important contributor to both reduced systolic function
and arrhythmias.
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Figure 1. RyR2 FRET CaM binding and Z-line total CaM binding
A, FRET images for 20 and 500 nM acceptor [F-CaM], while keeping donor (F-FKBP) saturated. Donor fluorescence decreases
and FRET signal increases at higher acceptor [F-CaM]. B, Acceptor (FRET) signal fit with single saturable binding isotherm
(n=11-13). C, Donor quench and acceptor FRET are linearly related. D, Z-line images for direct F-CaM excitation at 20 and 500
[F-CaM]. E, binding affinity fitted for CaM at Z-line (n=11-13), reflecting the Kd and total CaM (Bmax). F, Calibration of F-
CaM fluorescence for different bath [F-CaM].
Yang et al. Page 17






















Figure 2. Binding kinetics of CaM-RyR2
A, Representative time course of FRET (CaM fluoresence upon F-FKBP excitation) for 20nM F-CaM wash-in/off. CaM-RyR2
kon, koff and Kd are indicated (n=5). B, Recovery of photobleached FRET striation image in 20 nM [F-CaM] imaged at indicated
times. C, FRAP rate constants (kFRAP; single-exponential fits) at 15 and 30 nM F-CaM. D, kon (slope) and koff (intercept) are
extracted from linear regression fitting (n=8-10), and Kd is inferred.
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Figure 3. Percentage of Z-line CaM that is on RyR2
A, FRET images in saturating F-CaM and FFKBP12.6 conditions for WT and RyR2ADA/+. B, Z-line bound F-CaM images
(direct F-CaM excitation) for WT and RyR2ADA/+. C, Steady state CaM binding, with Bmax normalized to WT level and with
Kd inferred (n=12-20). D, Total Z-line associated F-CaM with Bmax and Kd for RyR2ADA/+ and WT mice (n=14-20).
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Figure 4. Diastolic Ca2+ leak in permeabilized myocytes
A, Confocal line images of Ca2+ sparks for 50nM [Ca2+] in WT and RyRADA/+ mice. B, Mean Ca2+ spark frequency and SR
Ca2+ content for WT and RyRADA/+ mice (±CaMKII inhibitor AIP). C, Confocal line scan at 100nM [Ca2+], showing a Ca2+
wave for RyRADA/+, but not for WT mouse. D, Percentage of myocytes showing Ca2+ waves and SR Ca2+ content for WT and
RyRADA/+ mice.
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Figure 5. Ca2+ transients in intact myocytes
A, Representative Ca2+ transients and SR Ca2+ content (assessed by 10 mM caffeine exposure) during at 1 Hz stimulation with
and without isoproternol (ISO; 50nM) for WT and RyR2ADA/+ mice. B, Average twitch transients amplitude (ΔF/F0). C, time
constant of twitch [Ca2+]i decline. D, SR Ca2+ content (amplitude of caffeine-induced Ca transient). E, Fractional SR Ca2+
release (ratio for twitch Ca2+ transient amplitude to caffeine-induced Ca2+ release).
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Figure 6. Arrhythmogenic Ca2+ waves in isoproterenol-treated myocytes
A, representative line-scan image of Ca2+ wave (sloping [Ca2+] rise) and triggered activity in intact myocyte with 50 nm ISO.
The almost instantaneous spread of SR Ca2+ release at triggered beats indicates that action potentials were induced. B,
Percentage of myocytes exhibiting Ca2+ waves and triggered activity for WT (n=24) and RyRADA/+ (n=22).
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Figure 7. Effect of caffeine plus ISO on ventricular arrhythmia (RyR2ADA/+)
A, representative ECG recording for RyR2ADA/+ mice, severe ventricular arrhythmia (sustained bigeminy, bidirectional VT and
polymorphic VT) were induced by ISO plus caffeine. B, 100% of RyR2ADA/+ mice exhibit sustained bigiminy (> 20min); 60%
RyR2ADA/+ mice exhibit typical bidirectional VT, and VT (bidirectional or polymorphic) episode is 4.5/mouse.
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Figure 8. CaM/FKBP12.6 binding affinity to RyR2 in HF myocytes
A, FRET detection and steady-state concentration-dependant binding, Kd of CaM-RyR2 was measured in HF myocytes (n=18).
B, Kd for FKBP12.6-RyR2 was measured by steady-state binding in HF myocytes (n=18-22). C, for Kd range (20 nM), there is a
significant decrease CaM-RyR2 associate rate for HF, but with same Bmax (in saturating condition). D, for Kd range or
saturating condition (Bmax), the FKBP12.6-RyR2 associate rate are unchanged for control and HF myocytes
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